Gene silencing of c-Met leads to brain metastasis inhibitory effects

Clinical and Experimental Metastasis

Volumn 30, Issue 7, 2013, Pages 845-854

  Lee, Se Jeong ^a,b   Seol, Ho Jun ^a   Lee, Hye Won ^a,b   Kang, Won Young ^a,b   Kang, Bong Gu ^a,b   Jin, Juyoun ^a,b   Jo, Mi Young ^a,b   Jin, Younggeon ^a,b   Lee, Jung Il ^a   Joo, Kyeung Min ^a,b   Nam, Do Hyun ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Brain metastasis; c Met; Epithelial mesenchymal transition; Migration; ShRNA

Indexed keywords

SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METASTASIS; CONTROLLED STUDY; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME;

ANIMALS; BASE SEQUENCE; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMANS; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84890429110     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9584-7     Document Type: Article

References (24)

1. Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533-540
2. Bladt F, Riethmacher D, Isenmann S et al (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768-771
3. Schmidt C, Bladt F, Goedecke S et al (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373:699-702
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
5. Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31:49-58
6. Christensen JG, Schreck R, Burrows J et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355
7. Hochgrafe F, Zhang L, O'Toole SA et al (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 70:9391-9401
8. Previdi S, Maroni P, Matteucci E et al (2010) Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 46:1679-1691
9. Ponzo MG, Lesurf R, Petkiewicz S et al (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106:12903-12908
10. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-Cadherin promotes motility in human breast cancer cells regardless of their e-cadherin expression. J Cell Biol 147:631-643
11. Hazan RB, Phillips GR, Qiao RF et al (2000) Exogenous expression of n-cadherin in breast cancer cells induces cell migration, invasion, and meta. J Cell Biol 148:779-790
12. Shattuck DL, Miller JK, Carraway KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68:1471-1477
13. Benedettini E, Sholl LM, Peyton M et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177:415-423
14. Kong DS, Song SY, Kim DH et al (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115:140-148
15. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214
16. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568-2581
17. Yehiely F, Moyano JV, Evans JR et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12:537-544
18. Goncalves A, Charafe-Jauffret E, Bertucci F et al (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420-1433
19. Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38:830-841
20. Ponzo MG, Park M (2010) The met receptor tyrosine kinase and basal breast cancer. Cell Cycle 9:1043-1050
21. Turner N, Lambros MB, Horlings HM et al (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013-2023
22. Schneider BP, Winer EP, Foulkes WD et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010-8018
23. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
24. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500